Hundred billion "chronic disease market" is very attractive, Yangtze River, East China Medicine Show your powers and speed up the layout

[pharmaceutical network market analysis] at present, China's elderly population has reached 249 million With the increasing of aging, the economic burden caused by chronic diseases will further increase According to some data, the death caused by chronic diseases has accounted for 85% of the total death, and the disease burden caused by chronic diseases has accounted for 70% of the total disease burden Photo source: chronic disease, also known as non communicable disease (NCD), refers to a long-term, incurable and almost incurable disease It is the result of comprehensive effects of genetic, physiological, environmental and behavioral factors, including malignant tumors, cardiovascular and cerebrovascular diseases, chronic lung diseases, mental diseases, diabetes, occupational diseases, nutritional and metabolic diseases and genetic diseases According to the data statistics of domestic sample hospitals, in 2018, antineoplastic drugs ranked third, with a sales volume of 26.5 billion yuan, accounting for 11.6%; cardiovascular system drugs ranked fourth, with a sales volume of 22.6 billion yuan, accounting for 10.0%; endocrine and metabolic regulation drugs (diabetes) ranked seventh, with a sales volume of 13.4 billion yuan, accounting for 5.9%; respiratory system drugs ranked tenth, with a sales volume of 8.1 billion yuan, accounting for 3.5% The total sales volume of four kinds of drugs is 70.6 billion yuan, accounting for 31.2% of the overall market In fact, in recent years, with the aging and the increasing pressure of medical insurance, the state is paying more and more attention to the field of chronic medicine In addition to continuously issuing the opinions on the protection of chronic medicine, more and more chronic medicine will be included in the list of national and local procurement with volume For example, recently, Hebei drug procurement center issued the document of centralized procurement of drugs for hypertension and diabetes outpatient service for urban and rural residents in Hebei Province, which will focus on the procurement of 15 outpatient drugs for hypertension and diabetes for urban and rural residents, including 9 varieties of hypertension and 6 varieties of diabetes, and the Chinese patent medicine Xiaoke pill is also listed In addition, it is also reported that after 25 "4 + 7" varieties, the national third wheel belt procurement is also expected to continue to include multiple chronic disease drugs As early as July this year, the State Council's opinions on the implementation of healthy China action put forward that China will carry out prevention and control actions against four major chronic diseases: cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases and diabetes At the beginning of October, the state health insurance bureau, the Ministry of finance, the State Health Commission and the State Drug Administration jointly issued the guiding opinions on improving the outpatient medication guarantee mechanism of urban and rural residents with hypertension and diabetes, which clearly included the medication of hypertension and diabetes in the medical insurance reimbursement, and the proportion of reported marketing will reach more than 50% In recent years, more provinces have responded to the call of the state to successively issue overall planning policies on drugs used in outpatients of hypertension and diabetes According to incomplete statistics, there are already Shandong, Sichuan, Shaanxi, Jiangxi, Jiangsu, Zhejiang, Anhui, Fujian, Guangxi, Guizhou, Hebei, Ningxia, Liaoning, Gansu, Shanxi, Yunnan, Chongqing 25 provinces and cities printed and distributed provincial-level policy documents on outpatient medication of hypertension and diabetes The various advantages of the policy have also attracted many pharmaceutical companies to accelerate the layout of the chronic disease drug market For example, at the end of May, Pfizer settled its global headquarters of "Pfizer puqiang", a non infectious disease (including cardiovascular and cerebrovascular diseases, pain and neurological diseases, mental diseases, urinary diseases and eye diseases) in Shanghai, which is also the first global headquarters set up by multinational pharmaceutical companies in China This foreign and domestic pharmaceutical enterprises, such as Yuheng pharmaceutical, Cr Shuanghe and many other pharmaceutical enterprises, also began to actively layout the slow disease field as early as last year, even at a high premium to acquire related enterprises In fact, the layout of chronic disease drug market of pharmaceutical enterprises can also be seen from the consistency evaluation Taking diabetes and hypertension drug overrated as an example, there are data showing that up to now, there are 10 varieties of diabetes drugs passing or deemed passing the consistency evaluation The popular varieties are metformin hydrochloride tablets, metformin hydrochloride sustained-release tablets and glimepiride tablets There are 11, 11 and 6 enterprises that have been evaluated respectively, and the enterprises that have been evaluated respectively include Ouyi, Yangzijiang, Huadong pharmaceutical, LVYE pharmaceutical, etc However, the market competition of antihypertensive drugs is more intense Up to now, there are 18 varieties of antihypertensive drugs that have passed or deemed to pass the consistency evaluation There are 8 varieties of three evaluated enterprises, namely olmesartan ester tablets, enalapril maleate tablets, captopril tablets, candesartan ester tablets, irbesartan hydrochlorothiazide tablets, irbesartan tablets, indapamide tablets and amlodipine besylate tablets Among them, there are 8 varieties of 3 evaluated enterprises Generally speaking, aging has been the stage and trend of social and economic development, and the continuous growth of medical expenses brought by it also makes the pressure of medical insurance more and more In the future, China and local governments will continue to purchase drugs for chronic diseases on a large scale While generic drugs replace high price original research and let patients use high-quality and low price products, the domestic mainstream pharmaceutical companies accelerate the transformation to innovative drug research and development, or will become the result orientation of the development of chronic disease drug market.